Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 4Completed 4Unknown 3Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Breast Neoplasms 6384Neoplasms 5356Prostatic Neoplasms 2964Carcinoma, Non-Small-Cell Lung 2704Colorectal Neoplasms 2674Lung Neoplasms 2262Multiple Myeloma 1656Lymphoma 1598Neoplasm Metastasis 1550Leukemia, Myeloid, Acute 1537Melanoma 1484Pancreatic Neoplasms 1470Ovarian Neoplasms 1420Leukemia 1387Head and Neck Neoplasms 1283Precursor Cell Lymphoblastic Leukemia-Lymphoma 1279Lymphoma, Non-Hodgkin 1226Colonic Neoplasms 1157Carcinoma, Hepatocellular 1141Stomach Neoplasms 1126Leukemia, Lymphocytic, Chronic, B-Cell 1089Brain Neoplasms 1048Rectal Neoplasms 979Lymphoma, Follicular 978Recurrence 971Uterine Cervical Neoplasms 923Glioblastoma 916Carcinoma, Renal Cell 881Lymphoma, Large B-Cell, Diffuse 851Hodgkin Disease 775

Interventions

Paclitaxel 2Tocotrienols 1Lenalidomide 1EP-100 membrane-disrupting peptide 1Carboplatin 1Bevacizumab 1AC 7700 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Ovarian Cancer Recurrent × Clear all
NCT04175470 2025-01-03

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

Vejle Hospital

Phase 2 Completed
20 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT01111903 2016-03-17

REV

ARCAGY/ GINECO GROUP

Phase 1/2 Completed
67 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT01332656 2015-12-21

OPSALIN

Sanofi

Phase 2 Completed
154 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT01485848 2014-06-10

ESP2011-002

Esperance Pharmaceuticals Inc

Phase 2 Completed
49 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡